Based on a donation by the Wyeth pharmaceutical company, GAVI recently launched the pneumococcal vaccine, Prevenar, in Rwanda, a first in Africa. Experts question the suitability of the vaccine in the African context, and GAVI’s decision to approve its use.

Development Today is a subscription-based journal published with 20 issues a year. To subscribe click here.

If you are already a subscriber to Development Today please log in.

Would you like to know more about Development Today? Click here.

Print this article